• Publications
  • Influence
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
TLDR
A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
TLDR
A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
TLDR
An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
TLDR
Thirteen categories of breast tumor markers were considered, six of which were new for the guideline, and certain multiparameter gene expression assays not all applications for these markers were supported, however.
Reporting recommendations for tumor marker prognostic studies (REMARK).
TLDR
These guidelines are designed to encourage transparent and complete reporting of tumor marker studies so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.
TLDR
Thirteen categories of breast tumor markers were considered, six of which were new for the guideline, and not all applications for these markers were supported, however.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
TLDR
An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
TLDR
A Tumor Marker Utility Grading System (TMUGS) will establish a standardized analytic technique to evaluate clinical utility of known and future tumor markers and to establish an investigational agenda for evaluation of new tumor markers.
REporting recommendations for tumor MARKer prognostic studies (REMARK)
TLDR
The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
TLDR
The REMARK checklist is expanded to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report.
...
1
2
3
4
5
...